A Combination Study With Ridaforolimus (MK8669) and Dalotuzumab (MK0646) in Patients With Advanced Cancer (8669-004)
This study is being done to find the best tolerated dose of ridaforolimus and dalotuzumab in patients who have advanced cancer and to observe any anti-tumor activity in these patients.
Neoplasms
DRUG: Comparator: ridaforolimus + dalotuzumab
To determine the toxicity profile, maximum tolerated dose and recommended phase II dose., MTD from Day 1 to Day 28 in Cycle 1 for disease progression
To measure pharmacokinetic and pharmacodynamic parameters with oral ridaforolimus as a single agent and in combination with dalotuzumab, At prescribed timepoints as defined in the protocol
Ridaforolimus (MK8669/AP23573) was also known as deforolimus until May 2009